/LBLTF

LBLTF Stock - Lattice Biologics Ltd.

Q: What is the analyst price target for LBLTF?

Analyst price target information is not currently available for LBLTF.

Q: What is LBLTF's market cap?

Market capitalization information is not currently available for LBLTF.

Healthcare|Medical - Devices|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for LBLTF

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2016

FY2017

FY2018

FY2019

FY2020

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.97

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2020	FY2019	FY2018	FY2017	FY2016
Revenue	$2.46M	$2.19M	$1.16M	$2.74M	$3.78M
Gross Profit	$1.02M	$942,761	$541,154	$571,110	$816,693
Gross Margin	41.4%	43.1%	46.9%	20.9%	21.6%
Operating Income	$-336,000	$-565,000	$-1,329,000	$-2,590,000	$-3,450,000
Net Income	$-1,483,000	$-1,012,000	$-1,231,000	$-1,525,000	$-7,852,000
Net Margin	-60.2%	-46.2%	-106.6%	-55.7%	-207.8%
EPS	$-0.01	$-0.01	$-0.01	$-0.02	$-0.16

Company Overview

Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic products for use in the field of bone regeneration in dental, spine, and general orthopedic indications worldwide. It develops novel amniotic fluid-based products, such as AmnioBoost and AmnioBlast. The company also offers traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, hernia repair, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior and posterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.

Visit Website

Frequently Asked Questions about LBLTF

What is LBLTF's current stock price?

Lattice Biologics Ltd. (LBLTF) is currently trading at $0.00 per share. The stock has moved +0.00% today.

What is the analyst price target for LBLTF?

No analyst price targets are currently available for this stock.

What sector is Lattice Biologics Ltd. in?

Lattice Biologics Ltd. operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the OTC exchange.

What is LBLTF's market cap?

Lattice Biologics Ltd. has a market capitalization of $0.00 billion, making it a small-cap company.

Does LBLTF pay dividends?

No, Lattice Biologics Ltd. does not currently pay a dividend to shareholders.